Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis
复制标题
预防性替诺福韦艾拉酚胺治疗乙型肝炎病毒再激活和再激活相关性肝炎
DOI：
10.1002/jmv.28452
复制
发表时间：
2023
影响因子：
12.7
通讯作者：
et al.,
中科院分区：
文献类型：
--
作者：
Suda Goki;et al.,
替诺福韦艾拉酚胺（TAF）是一种新型的替诺福韦前药，其预防B型肝炎病毒（HBV）再激活的效果尚未有前瞻性研究报道。这项多中心前瞻性研究入组了在抗肿瘤或免疫抑制治疗前接受TAF预防HBV再激活的HBV携带者，以及发生HBV再激活并接受TAF预防HBV再激活相关肝炎的HBV感染消退患者。在开始TAF后6个月和12个月评价了预防性TAF在预防HBV再激活和HBV再激活相关肝炎方面的疗效。总体而言，110例患者接受了TAF治疗，以预防HBV再激活或HBV再激活相关肝炎。3例患者死于原发病，而1例患者在开始TAF后6个月内转至另一家医院。7例患者死于原发病，5例患者在开始TAF后12个月内转至另一家医院。因此，分别在开始TAF后6个月和12个月对106例和94例（77例HBV感染患者，17例既往HBV感染患者）患者进行了评价。6个月和12个月后，无患者发生HBV再激活、HBV再激活相关肝炎或因HBV再激活或TAF不良事件而停药。TAF可有效预防HBV再激活和HBV再激活相关肝炎。
No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing hepatitis B virus (HBV) reactivation has yet been reported. This multicenter prospective study enrolled HBV‐carriers who received TAF to prevent HBV reactivation before antitumor or immunosuppressive therapy, and patients with resolved HBV infection who experienced HBV‐reactivation and received TAF to prevent HBV reactivation‐related hepatitis. The efficacy of prophylactic TAF in preventing HBV reactivation and HBV reactivation‐related hepatitis was evaluated at 6 and 12 months after initiating TAF. Overall, 110 patients were administered TAF to prevent HBV reactivation or HBV reactivation‐related hepatitis. Three patients died owing to primary disease, whereas one patient was transferred to another hospital within 6 months after initiating TAF. Seven patients died due to primary disease, and five patients were transferred to another hospital within 12 months after initiating TAF. Therefore, 106 and 94 (77 patients with HBV infection, 17 with previous‐HBV infection) patients were evaluated at 6 and 12 months after initiating TAF, respectively. No patient experienced HBV reactivation, HBV reactivation‐related hepatitis, or treatment discontinuation due to HBV reactivation or adverse events of TAF after 6 and 12 months. TAF could effectively prevent HBV reactivation and HBV reactivation‐related hepatitis.
登录
查看更多内容
DOI：
10.1002/hep.27609
发表时间：
2015-02
期刊：
Hepatology (Baltimore, Md.)
影响因子：
--
作者：
Di Bisceglie AM;Lok AS;Martin P;Terrault N;Perrillo RP;Hoofnagle JH
通讯作者：
Hoofnagle JH
影响因子：
6.6
作者：
Sarin SK;Kumar M;Lau GK;Abbas Z;Chan HL;Chen CJ;Chen DS;Chen HL;Chen PJ;Chien RN;Dokmeci AK;Gane E;Hou JL;Jafri W;Jia J;Kim JH;Lai CL;Lee HC;Lim SG;Liu CJ;Locarnini S;Al Mahtab M;Mohamed R;Omata M;Park J;Piratvisuth T;Sharma BC;Sollano J;Wang FS;Wei L;Yuen MF;Zheng SS;Kao JH
通讯作者：
Kao JH
影响因子：
4.2
作者：
Ando, Ryoichi;Asahina, Yasuhiro;Yotsuyanagi, Hiroshi
通讯作者：
Yotsuyanagi, Hiroshi
影响因子：
7.6
作者：
Wong, Grace Lai-Hung;Chan, Henry Lik-Yuen;Wong, Vincent Wai-Sun
通讯作者：
Wong, Vincent Wai-Sun
DOI：
10.1002/hep.29800
发表时间：
2018-04
期刊：
Hepatology (Baltimore, Md.)
影响因子：
--
作者：
Terrault NA;Lok ASF;McMahon BJ;Chang KM;Hwang JP;Jonas MM;Brown RS Jr;Bzowej NH;Wong JB
通讯作者：
Wong JB